Project Grant DP2AG093209

Award Date 9/15/24
Completion Date 8/31/27
Dollars Obligated $1.5M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Aging
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This $1,024,510 National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases project grant funds research at the University of California, San Francisco into simultaneous imaging of tissue biochemistry and metabolism associated with biomechanics in patellofemoral joint osteoarthritis. The research will conduct a longitudinal cohort study of 100 individuals with isolated patellofemoral joint osteoarthritis followed over two time points. Simultaneous positron...
This three-year, $906,000 project grant from the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases will fund research into obesity-promoting protein malonylation and its role in chondrocyte metabolic dysfunction and osteoarthritis development. Specifically, the grantee - Ohio University - will investigate how obesity accelerates osteoarthritis through "carbon stress," which causes metabolic byproducts to accumulate in cartilage...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research into the molecular regulatory mechanisms of a cartilage-enriched G protein-coupled receptor (GPCR) named ADGRG6 in maintaining joint homeostasis and preventing osteoarthritis (OA). The $426,889 award, effective from April 10, 2025 to March 31, 2030, will enable the University...
The National Institute on Aging (NIA) awarded a $639,997 Project Grant (CFDA 93.866 - Aging Research) to The Spaulding Rehabilitation Hospital Corporation to investigate how exercise regulates molecular circuitry in cartilage and the knee joint to promote cartilage integrity and joint health in the context of knee osteoarthritis. The 5-year project aims to provide mechanistic insights into how molecular cargoes in circulating extracellular vesicles impact osteoarthritic knee joint health in a...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $115,949 to The Regents of the University of California, San Francisco (UCSF) to support research on the control of adipose immune-stromal niche topography in obesity. The primary objectives are to delineate adipose tissue topography using spatial sequencing, microscopy, and flow cytometry to identify novel signaling or cell...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to determine the role of the mechanosensitive protein PIEZO1 in joint homeostasis and osteoarthritis (OA) susceptibility. The $691,089 award, effective July 15, 2025 through June 30, 2030, will fund studies at the University of Utah to: 1) identify how mutations in PIEZO1...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research to investigate the mechanistic links between gait biomechanics and the development of knee osteoarthritis (KOA). The $644,152 award, which runs from January 2025 to December 2029, will be used by the University of North Carolina at Chapel Hill to: 1) determine the acute in vivo...
The National Institutes of Health Office of the Director awarded $2,907,000 under the Trans-NIH Research Support program to the Regents of the University of California, San Francisco for a project grant titled "Discovering Mechanisms of Tissue-Resident Immune Aging." The grant will fund research from September 2022 through August 2025 to study the mechanisms driving dysregulation of the aging adipose tissue-resident immune compartment. Specifically, the researchers will use inducible...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to define the systemic mechanisms by which adipose (fat) tissue communicates with the knee joint to drive the development of osteoarthritis (OA). The $1,476,001 award to the Regents of the University of California, San Francisco will fund a comprehensive investigation of three potential interorgan crosstalk pathways: signaling through secreted factors, cell migration, and nervous system mediation. The research seeks to unravel the fundamental mechanisms underlying the surprising finding that OA may have systemic origins involving adipose tissue, rather than solely local joint pathology. By elucidating these mechanisms, the project aims to enable the development of first-in-class disease-modifying treatments that can improve whole-body health and longevity for OA patients. The award period runs from Sep 15, 2024 to Aug 31, 2027.

Generated 7/1/25, 4:13 AM